Newsletters - BioWorld
WEBBioWorld Science. Cumulus Oncology Ltd. is in the thick of raising a $50 million series A round as its model of sourcing novel drug targets emerging from academia, shaping them up... Highfield Biopharmaceuticals Inc. has filed an IND application with China’s National Medical Products Administration (NMPA) to conduct a clinical trial of HF-50,...
| BioWorld
WEBFeb 10, 1995 · Telios officials could not be reached for comment. The company'schief financial officer told BioWorld on Jan. 15 that Telios had $17million in cash, including the $13 million ordered invested insecurities. The Integra offer is contingent upon confirmation of a reorganizationplan, Telios having cash and receivables of at least $12 million ...
China - BioWorld
WEBSep. 3, 2024. By Marian (YoonJee) Chu. No Comments. Jacobio Pharmaceuticals Group Co. Ltd. out-licensed rights for two lung cancer assets in China to Shanghai Allist Pharmaceuticals Co. Ltd. through a potential ¥900 million (US$126.4 million) deal. Beijing-headquartered Jacobio said Aug. 30 that it signed off development, regulatory and ...
Welcome to the new BioWorld Science
WEBSep 12, 2022 · BioWorld Science has now been migrated onto the same platform as the full suite of BioWorld news services, providing an improved experience and expanded news offering. The new site features many enhancements, which you can read about here.Frequently Asked Questions are answered here. In addition to BioWorld Science content, you can now read headlines and summaries from the flagship news ...
Siemens gets CE mark for neurofilament light chain blood
WEBJun 17, 2024 · Siemens Healthineers AG has received CE mark for a neurofilament light chain assay to help with the early diagnosis of multiple sclerosis and aid in predicting the risk of relapse in patients suffering from the disease. The test developed in collaboration with Novartis Pharma AG will be launched in Europe …
Biopharma funding hits $5.65B in November, with 18% increase YTD
WEBDec 8, 2023 · In November, the biopharma industry raised $5.65 billion in total financings. While down from $11.6 billion tracked by BioWorld in October, overall financings are tracking ahead of last year. Biopharma funding has maintained an average of $6.1 billion per month in 2023, surpassing the $5.07 billion monthly average throughout 2022.
Appointments and advancements - BioWorld
WEB3 days ago · Appointments and advancements for August 13, 2024. New hires and promotions in the med-tech industry, including: Biocartis, Endra Life Sciences, Mindera Health, Pinkdx, Solvd Health. Breaking news and analysis of the global biotechnology, pharmaceutical, medical device and medical technology sectors. In-depth coverage of innovation, business ...
Mutated tumor suppressors may become oncogenes, potential
WEBAug 23, 2024 · Mutated tumor suppressors may become oncogenes, potential drug targets. A new study has shown that when a gene is mutated and its copy number is altered, the risk of that gene contributing to the development of cancer increases. Although it was already known that both variations together promoted cancer, …
Deals - BioWorld
WEBSep 13, 2024 · Epimab licenses BCMA bispecific to startup Vignette in $635M deal. In a deal that brings $60 million in cash and equity up front, plus up to $575 million in milestone payments, Shanghai-based Epimab Biotherapeutics Inc. and San Diego-based Vignette Bio Inc. entered a licensing agreement for Epimab’s …
| BioWorld
WEBJul 17, 2024 · A non-traditional route for financing has been the path to success for Fibrobiologics Inc. In the newest BioWorld Insider podcast, CEO Pete O’Heeron offers insight into the company’s unusual path to a Nasdaq listing in January. SPACs, reverse mergers and traditional IPOs weren’t attractive enough for Fibrobiologics’ management or board, so they decided to go public through a direct ...
Skip to content